Epitalon 10mg vial

NOT FOR HUMAN CONSUMPTION

Epitalon (Ala–Glu–Asp–Gly; AGAG) is a short tetrapeptide derived from the bovine-pineal extract “epithalamin,” developed by the St. Petersburg/Khavinson group. It’s marketed as a “geroprotective” peptide with proposed actions on telomerase activation, chromatin remodeling, circadian signaling, and stress-response pathways. It is not FDA/EMA-approved; human evidence consists mostly of small, regionally published trials and observational series.

Additional Benefits of Epitalon Now Under Investigation

2. Molecular Mechanism of Action

2.1 Proposed pharmacodynamics

• Telomerase/epigenetic: Enhances TERT expression and may influence heterochromatin maintenance at telomeric/subtelomeric regions.

• Pineal/circadian: Modulates melatonin synthesis and clock-gene output (e.g., BMAL1/Per axes), supporting sleep–wake regulation.

• Stress/inflammation: Down-shifts NF-κB, supports Nrf2 antioxidant responses, improves mitochondrial redoxmetrics in models.

2.2 Down-stream biology

3. Pharmacokinetics

• Route: Reported SC/IM injections (common in publications), intranasal, and occasional oral/sublingual use; no standardized formulation.

• Absorption/half-life: Very short plasma t½ for the tetrapeptide (minutes–hours); hypothesized epigenetic/circadian effects may outlast exposure.

• Distribution/clearance: Rapid tissue uptake and renal peptidase clearance expected; human PK is not well characterized.

4. Pre-clinical and Translational Evidence

4.1 Cellular/animal

• In vitro: TERT up-regulation, telomere preservation, improved chromosomal stability, reduced β-gal senescence staining.

• In vivo (rodents): Improved survival curves in some strains, antioxidant enzyme normalization, tumor latencyshifts in specific models, and circadian improvements.

4.2 Human studies

• Small, mostly open-label or regionally randomized trials report improved melatonin profiles, sleep, immune markers, and some metabolic indices; multi-year observational data suggest mortality reduction when combined with other “cytomedins,” but methodology limits causal claims.

Evidence quality note: Most human data are low–moderate quality, with limited blinded, placebo-controlled trials and variable assay rigor for telomeres and hormones.

5. Emerging Clinical Interests

6. Safety and Tolerability

• Common: Injection-site discomfort, transient fatigue or alertness changes (timing-dependent), headache, mild GI upset with oral forms.

• Endocrine: Possible melatonin-related daytime sleepiness if dosed late morning; rare vivid dreams.

• Immunologic: No strong signals of immunosuppression; long-term immune stimulation vs regulation remains uncertain.

• Oncology: Theoretical concern that telomerase activation might promote neoplastic cell persistence; animal data are mixed. Avoid in active cancer outside studies.

• Drug interactions: Caution with sedatives (sleep synergy) and agents affecting circadian timing; minimal CYP interplay expected.

• Special populations: Insufficient data in pregnancy, autoimmune disease, or active malignancy, avoid outside IRB protocols.

Comparative safety matrix

7. Regulatory Landscape

• Not approved by FDA/EMA for any indication.

• Available via research-chemical vendors or compounding in some locales; quality varies.

• Use should remain within research/IRB-guided settings; marketing claims of “anti-aging cure” are not evidence-based.

8. Practical Use & Future Directions

• If studied (research context): Consider cyclic courses (e.g., 10–20 days per quarter) aligned to sleep schedule(evening dosing) and track sleep metrics, inflammatory markers, and (if relevant) telomere assays with consistent methodology.

• Lifestyle stack: Prioritize sleep hygiene, daytime light, exercise, protein sufficiency, and metabolic health, these have stronger, proven effects on longevity markers.

• Trials needed:

  • Multicenter, randomized, double-blind trials with actigraphy, melatonin profiles, immune panels, and clinical endpoints.

  • Standardized PK/PD and bioanalytical validation for telomerase/telomere outcomes.

  • Long-term safety focused on oncology and immune balance.

Selected References

• Aging-related peptide literature from the St. Petersburg Institute (epithalamin/Epitalon): telomerase/telomere, circadian, and immune observations.

• Redox Biology; Free Radical Biology & Medicine, Antioxidant and NF-κB/Nrf2 signaling under peptide geroprotectors (preclinical).

• Chronobiology International; Sleep Medicine, Melatonin/circadian endpoints in older adults (context for pineal-axis modulation).

• Immunity; Frontiers in Immunology, Immunosenescence frameworks relevant to peptide-mediated immune tuning.

• Oncogene; Cancer Research, Telomerase biology and theoretical oncologic implications of telomerase activation.